GA
PTCT icon

Gateway Advisory’s PTC Therapeutics PTCT Stock Holding History

Gateway Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-4,000
Closed -$207K – 42
2014
Q4 		$207K Buy
+4,000
New +$176K 0.09% 34

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Gateway Advisory's PTCT Position: Q1 2015 in Review

Gateway Advisory sold out of PTC Therapeutics (PTCT) in Q1 2015, closing a stake of 4,000 shares — an estimated $207K sold.

Gateway Advisory first reported a position in PTCT in Q4 2014 and held it in 1 quarter. The position peaked at $207K in Q4 2014. 157 funds tracked by Wall St. Rank hold PTCT as of Q1 2015.

  • Gateway Advisory reported no remaining PTC Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Gateway Advisory sold 4,000 PTC Therapeutics shares in Q1 2015, an estimated $207K.
  • Gateway Advisory first reported a position in PTC Therapeutics in Q4 2014 and held it in 1 quarter.
  • Gateway Advisory's PTC Therapeutics position peaked at $207K in Q4 2014.
  • 157 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2015.

Based on Gateway Advisory's 13F filing for Q1 2015, filed 1 May 2015.